26 September 2022 in IEEE Access
Personalized medicine provides more safe and effective treatment by individualizing the choice of drug and dose based on an individual’s genetic profile. Cancer patients’ response to anti-cancer treatments (drugs) is one of the foremost challenges in personalized medicine that releases the target treatment. Both size and availability of drug sensitivity data have motivated researchers to develop Artificial Intelligence (AI), based models, for predicting drug response to advance cancer treatment. The concerned AI models include Machine Learning (ML) and the recently advanced Deep Learning (DL) based models. This paper introduces both; a data federation method and a DL-based model for predicting drug response. The fundamental goal is to generalize the predictor so it will be able to predict the response to different drugs accurately. As the data has a considerable effect on any AI model, the data federation is utilized to consolidate the data. The proposed consolidation process is carried out to make each cell line contains gene expression data, its mutation profile, and drug response data. ML models such as Support Vector Machine (SVM) and Linear Regression (LR) are used along with Principal Component Analysis (PCA) for feature reduction, and the AI models have been tested with and without data federation. The results show that data federation enhanced the accuracy and decreased the Mean Square Error (MSE) by almost 25%. The proposed DL model uses dimension reduction encoders. The encoder is a DL model that uses unsupervised learning. It is trained by integrating an encoder with a decoder to achieve equality between the input and output. The proposed model has achieved the best accuracy compared to some other recent models in terms of the Pearson correlation coefficient (PCC) as a performance measure. In addition, the results show that the Enhanced Deep Drug Response prediction (Enhanced Deep-DR) model has achieved the best PCC value even with the largest number of genes and drugs, which proves the high capacity and efficiency of the proposed model. Convolutional Neural Network (CNN) based-model is also implemented; it achieves higher accuracy in predicting the drug response than in some other DL-based models but less than the Enhanced Deep learning. The Enhanced Deep-DR achieves better accuracy within the range of 5% to 12% than other DL-models.
1 March 2023 in International Journal of Intelligent Computing and Information Sciences
Recently, efforts are exerted on cancer treatment prediction based on the biomarkers related to the tumor. Gene expression and mutation profiles are the most used biomarkers for cancer prediction. Machine learning and deep learning algorithms have been used to predict drug response. The recent research show that the performance of deep learning models is better than the performance of machine learning based one. In this paper, we introduce the use of Convolutional Neural Network (CNN) models to predict different drugs response. DeepInsight algorithm used to convert the input data to images to be more suitable as input to the CNN. We proposed 3 different pretrained CNNs-models (InceptionV3, Xception, EfficientNetB7) with alternatives in their settings in the training process and modification in their architectures to be able to predict the drug response using IC50 regression values. Those models are selected due to their efficiency for ImageNet applications.the proposed modified Xception model achieves the best accuracy over the 2 others. At first, the whole data input passes through DeepInsight which converts the gene expression data and mutation data to images. Dimension reduction is then applied using the helper technique inside the DeepIsignt. Comparative analysis with other Deep models, shows that the proposed approach improve the prediction accuracy in a range between 14% and 22% as a reduction in mean squared error (MSE)
1 October 2021 in QJM: An International Journal of Medicine
AAAmina Osama Mohamed Awwad
Amina Osama Mohamed Awwad
SMShaimaa Abdelsattar Mohammed
Shaimaa Abdelsattar Mohammed
Background: Pelviabdominal masses are common in children. It can be a leadig cause of considerable morbidity and mortality. Objective: To review the different pelviabdominal masses and their diagnostic criteria using the multidetector CT scans in order to build an approach for diagnosis. Methods: A retrospective study, conducted at Ain Shams University hospitals on children complaining of pelviabdominal masses, the patients were investigated using CT scans in the period between June 2018 till end of May 2019. Results: pelviabdominal CT scan of 70 patients were reviewed. Their age ranged from 7 days to 18 years old, the mean was 8 years of age (SD ± 5.5). 31 male : 39 female. Abdominal masses of pediatrics were congenital ( 9 case), neoplastic ( 20 cases), inflammatory ( 23 casaes) and post traumatic in origin (3 cases). The most common congenital masses were PUJO, neoplastic were neuroblastomas, inflammatory were abscess. Diagnostic approach should start with determination of the organ of origin followed by determination of its morphology and pattern of contrast enhancement. The kidney was found to be the most common organ of origin in 25.7% of cases followed by the adenxa. Conclusion: the organ of origin and morphology of the lesion are key imaging features that will help the radiologist reach a definitive diagnosis or deliver a possible differential diagnosis.